Media Coverage
2011/12/6: GenomeWeb. Spartan Bioscience begins Italian trial for CYP2C19 DNA test.
“Canada’s Spartan Bioscience said this week that it has launched a clinical trial in Italy to evaluate the company’s point-of-care CYP2C19 DNA test in guiding antiplatelet therapy in cardiac stent patients.”
2011/11/17: GenomeWeb. Canadian trial validates Spartan Bioscience’s point-of-care platform for PGx applications.
“Spartan Bioscience has completed a validation and proof-of-concept study in Canada showing the ability of its flagship point-of-care DNA testing system to identify patients carrying the CYP2C19*2 mutation at the time of cardiac catheterization and help guide appropriate anti-platelet therapy.”
2011/11/14: MD Conference Express. Findings from the RAPID GENE trial.
2011/11/9: TheHeart.org. RAPID GENE: Clopidogrel-response gene test makes point-of-care debut.
“A genotyping assay device billed as ‘the first point-of-care genetic test in medicine,’ which produces a result within 60 minutes, seems to accurately identify patients who carry a gene variant that signals reduced responsiveness to clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis).”
2011/1/10: GenomeWeb. Spartan Bioscience taps Germany’s Alere to distribute CYP2C19 testing platform.
“Canadian molecular diagnostics shop Spartan Bioscience said today that it has inked an exclusive distribution agreement with Germany’s Alere GmbH to distribute the Spartan RX CYP2C19 platform in Germany, Austria, and Switzerland.”
2010/12/20: GenomeWeb. Spartan Bioscience gets CE IVD Mark for ’sample-to-answer’ CYP2C19 testing platform.
“Canada’s Spartan Bioscience said today that its CYP2C19 molecular test, which runs on the company’s Spartan RX PCR-based point-of-care testing platform, has received a CE Mark for in vitro diagnostic use in Europe.”
2010/8/18: GenomeWeb. Spartan Bio aims to bring POC DNA testing to uncharted waters.
“With the recent launch of what it says is the first point-of-care DNA test, Spartan Bioscience is hoping to bring its technology to areas not presently served by molecular diagnostics.”
2010/8/12: GenomeWeb. Canada’s Spartan Bioscience launches POC DNA testing system for PGx applications.
“Canadian molecular diagnostics firm Spartan Biosciences this week unveiled the Spartan RX, a fully automated, point-of-care, PCR-based testing platform for personalized medicine.”
2010/8/11: GenomeWeb. Researchers studying two point-of-care tests to gauge PGx response to anti-platelet drugs.
“Vying to break into the point-of-care testing market to guide anti-platelet treatment in cardiac patients, at least two molecular diagnostics companies are studying the utility of their rapid tests in clinical trials.”
2010/8/11: Medical Device Daily. Spartan’s first test for new system ID’s gene mutation.
“Spartan Bioscience…reported the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine.”
